By Iain Gilbert
Date: Thursday 30 Oct 2025
(Sharecast News) - Pharmaceutical giant Eli Lilly posted stronger-than-expected third-quarter earnings and revenue on Thursday, fuelled by surging demand for its diabetes drug Mounjaro and weight-loss treatment Zepbound.
| Currency | US Dollars |
| Share Price | $ 925.81 |
| Change Today | $ 18.95 |
| % Change | 2.09 % |
| 52 Week High | $955.46 |
| 52 Week Low | $625.65 |
| Volume | 13,330 |
| Shares Issued | 948.17m |
| Market Cap | $877,825m |
| Beta | 0.69 |
| RiskGrade | 179 |
| Strong Buy | 11 |
| Buy | 11 |
| Neutral | 8 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 30 |

You are here: research